| pubmed-article:17580000 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17580000 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:17580000 | lifeskim:mentions | umls-concept:C0023418 | lld:lifeskim |
| pubmed-article:17580000 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:17580000 | lifeskim:mentions | umls-concept:C0018951 | lld:lifeskim |
| pubmed-article:17580000 | lifeskim:mentions | umls-concept:C0040648 | lld:lifeskim |
| pubmed-article:17580000 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:17580000 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:17580000 | lifeskim:mentions | umls-concept:C0060001 | lld:lifeskim |
| pubmed-article:17580000 | lifeskim:mentions | umls-concept:C2003905 | lld:lifeskim |
| pubmed-article:17580000 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17580000 | pubmed:dateCreated | 2007-6-20 | lld:pubmed |
| pubmed-article:17580000 | pubmed:abstractText | The CCAAT/enhancer binding protein alpha (C/EBPalpha or CEBPA) is the founding member of a family of related leucine zipper transcription factors that play important roles in myeloid differentiation. Targeted inactivation of C/EBPalpha in mice demonstrates its importance in the proper development and function of liver, adipose tissue, lung and haematopoietic tissues. C/EBPalpha is highly expressed in these differentiated tissues where it controls differentiation-dependent gene expression and inhibits cell proliferation. Learning more about the precise molecular functions of the C/EBPalpha protein and how these are affected by leukaemogenic mutations should lead to an improved understanding of the cellular functions that are disrupted in patients with AML. Decreased expression of C/EBPalpha but not C/EBPalpha mutation has been shown in patients with granulocytic leukaemias that are associated with translocations t(8;21), inv (16) or t(15;17). Derived fusion proteins repress C/EBPalpha expression. Differentiation therapy of some AML types is based on restoring C/EBPalpha function. However, apparently normal C/EBPalpha is overexpressed in BCP-ALL harbouring the translocation t(14; 19)(q32; q13). C/EBPalpha may exhibit oncogenic as well as tumour suppressor properties in human leukaemogenesis. C/EBPalpha mutations were not found in non-haematopoietic cancers. DNA hypermethylation of the upstream C/EBPalpha promoter region is responsible for very low C/EBPalpha expression in human lung and endometrial cancer. C/EBPalpha expression may be a biomarker for early detection of these cancers and DNA-modifying drugs such as demethylating agents and/or histone deacetylase inhibitors could be used in the treatment of these malignancies. | lld:pubmed |
| pubmed-article:17580000 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17580000 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17580000 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17580000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17580000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17580000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17580000 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17580000 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17580000 | pubmed:issn | 0015-5500 | lld:pubmed |
| pubmed-article:17580000 | pubmed:author | pubmed-author:FuchsOO | lld:pubmed |
| pubmed-article:17580000 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17580000 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:17580000 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17580000 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17580000 | pubmed:pagination | 97-108 | lld:pubmed |
| pubmed-article:17580000 | pubmed:meshHeading | pubmed-meshheading:17580000... | lld:pubmed |
| pubmed-article:17580000 | pubmed:meshHeading | pubmed-meshheading:17580000... | lld:pubmed |
| pubmed-article:17580000 | pubmed:meshHeading | pubmed-meshheading:17580000... | lld:pubmed |
| pubmed-article:17580000 | pubmed:meshHeading | pubmed-meshheading:17580000... | lld:pubmed |
| pubmed-article:17580000 | pubmed:meshHeading | pubmed-meshheading:17580000... | lld:pubmed |
| pubmed-article:17580000 | pubmed:meshHeading | pubmed-meshheading:17580000... | lld:pubmed |
| pubmed-article:17580000 | pubmed:meshHeading | pubmed-meshheading:17580000... | lld:pubmed |
| pubmed-article:17580000 | pubmed:meshHeading | pubmed-meshheading:17580000... | lld:pubmed |
| pubmed-article:17580000 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17580000 | pubmed:articleTitle | Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias. | lld:pubmed |
| pubmed-article:17580000 | pubmed:affiliation | Institute of Haematology and Blood Transfusion, Prague, Czech Republic. Ota.Fuchs@uhkt.cz | lld:pubmed |
| pubmed-article:17580000 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17580000 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:17580000 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17580000 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17580000 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17580000 | lld:pubmed |
